Psychiatr. praxi. 2026;27(1):60-62

Jak pomoci adolescentům s ADHD

Redakce

Zpracováno na základě přednášky MUDr. Jana Uhlíře. Porucha pozornosti s hyperaktivitou patří mezi nejčastější neurovývojové poruchy dětského a adolescentního věku a její projevy často významně ovlivňují školní i sociální fungování pacientů. V rámci kongresové přednášky, která zazněla na 22. konferenci Psychiatrie pro praxi v Olomouci ve dnech 27.-28. 11. 2025, se primář MUDr. Jan Uhlíř zaměřil na současné principy léčby ADHD v adolescenci, s důrazem na racionální indikaci farmakoterapie a praktické zkušenosti s nově dostupným lisdexamfetaminem v klinické praxi.

Published: March 23, 2026  Show citation

ACS AIP APA ASA Harvard Chicago Chicago Notes IEEE ISO690 MLA NLM Turabian Vancouver
Redakce. Jak pomoci adolescentům s ADHD. Psychiatr. praxi. 2026;27(1):60-62.
Share...
Download citation
  • BibTeX (.bib)
  • Bookends (.ris)
  • EasyBib (.ris)
  • EndNote (.enw)
  • EndNote 8 (.xml)
  • ISI WoS (.isi)
  • Medlars (.medlars)
  • Mendeley (.ris)
  • MODS (.xml)
  • Papers (.ris)
  • RefWorks (.txt)
  • RefManager (.ris)
  • RIS (.ris)
  • MS Word (.xml)
  • Zotero (.ris)
    • Purchase PDF - 60 CZK (2.5 EUR)
    will be unlocked 23.3.2027

    References

    1. Cortese S, Adamo N, Del Giovane C, et al. Comparative efficacy and tolerability of medications for attention-deficit hyperactivity disorder in children, adolescents, and adults: a systematic review and network meta-analysis. Lancet Psychiatry. 2018; 5: 727-738. doi: 10.1016/S2215-0366(18)30269-4. Go to original source... Go to PubMed...
    2. Findling RL, Childress AC, Cutler AJ, et al. Efficacy and safety of lisdexamfetamine dimesylate in adolescents with attention-deficit/hyperactivity disorder. J Am Acad Child Adolesc Psychiatry. 2011 Apr;50(4):395-405. doi: 10.1016/j.jaac.2011. 01. 007. Go to original source...
    3. Coghill DR, Caballero B, Shaw Sorooshian S, et al. A Systematic Review of the Safety of Lisdexamfetamine Dimesylate. CNS Drugs. 2014 May 1;28(6):497-511. doi: 10.1007/s40263-014-0166-2 Go to original source... Go to PubMed...

    Return to the content


    Psychiatry for Practice

    Madam, Sir,
    please be aware that the website on which you intend to enter, not the general public because it contains technical information about medicines, including advertisements relating to medicinal products. This information and communication professionals are solely under §2 of the Act n.40/1995 Coll. Is active persons authorized to prescribe or supply (hereinafter expert).
    Take note that if you are not an expert, you run the risk of danger to their health or the health of other persons, if you the obtained information improperly understood or interpreted, and especially advertising which may be part of this site, or whether you used it for self-diagnosis or medical treatment, whether in relation to each other in person or in relation to others.

    I declare:

    1. that I have met the above instruction
    2. I'm an expert within the meaning of the Act n.40/1995 Coll. the regulation of advertising, as amended, and I am aware of the risks that would be a person other than the expert input to these sites exhibited

    No
    Yes

    If your statement is not true, please be aware
    that brings the risk of danger to their health or the health of others.